利益冲突与免疫政策政府咨询专家的独立性评估
There has been increasing attention to financial conflicts of interest (COI) in public health research and policy making, with concerns that some decisions are not in the public interest. One notable problematic area is expert advisory committee (EAC).…
要点
- 魁北克免疫EAC成员对行业的独立性差异很大。
- 疫苗销售额最高的公司主要与已披露的COI相关联。
- EAC可用(In)DepScale更好地评估和披露影响专家的COI。
核心结论
- EAC成员对商业利益的独立性差异很大,疫苗销售额最高的公司主要与已披露的COI相关联。
- EAC可用(In)DepScale更好地评估和披露影响其专家的COI。
研究设计与样本
- 分析加拿大魁北克免疫专家咨询委员会(EAC)成员的COI披露,使用自行开发的(In)DepScale工具评估专家独立程度。
主要发现
- 专家对行业的独立性差异很大。
- 疫苗销售额最高的公司主要与已披露的COI相关联。
临床怎么用
- EAC可用(In)DepScale更好地评估和披露影响其专家的COI。
- 该量表未来可帮助管理风险并选择冲突较少的成员,以促进顾问和决策者的透明与信任文化。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There has been increasing attention to financial conflicts of interest (COI) in public health research and policy making, with concerns that some decisions are not in the public interest. One notable problematic area is expert advisory committee (EAC). While COI management has focused on disclosure, it could go further and assess experts' degree of (in)dependence with commercial interests. We analyzed COI disclosures of members of Québec's immunization EAC (in Canada) using (In)DepScale, a tool we developed for assessing experts' level of (in)dependence. We found great variability of independence with industry and that companies with the highest vaccine sales were predominantly associated with disclosed COIs. We argue that EACs can use the (In)DepScale to better assess and disclose the COIs that affect their experts. Going forward our scale could help manage risk and select members who are less conflicted to foster a culture of transparency and trust in advisors and policy-makers.
引用
- Bélisle-Pipon JC, Ringuette L, Cloutier AI, et al. Conflicts of interest and the (in)dependence of experts advising government on immunization policies. Vaccine. 2018. PMID: 30361123. doi:10.1016/j.vaccine.2018.10.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。